Aprea Reports Interim Phase 1 APR-1051 Data: Two PRs, 84% Target Engagement
APRE sits 36% above its 52-week low of $0.39.
Summary
Aprea presented interim Phase 1 data for WEE1 inhibitor APR-1051 showing two partial responses in PPP2R1A-mutated uterine cancers, five durable stable-disease patients, and WEE1 target engagement in 84% of evaluable patients, with a manageable safety profile. Enrollment is being refocused on uterine serous carcinoma and cyclin E-overexpressing ovarian cancer.
Key Events · Product Development and Regulatory · APRE
-
Interim Phase 1 Data Show Two Partial Responses
Of 56 patients treated in ACESOT-1051 as of the November 1, 2026 cutoff, 43 were evaluable: one confirmed and one unconfirmed RECIST 1.1 partial response in PPP2R1A-mutated uterine cancers, plus five stable-disease patients lasting more than four months.
-
WEE1 Target Engagement Confirmed in 84%
Paired skin biopsies showed at least 50% reduction in pCDK1-Y15 in 21 of 25 evaluable patients (84%) across multiple dose levels, supporting once-daily dosing with an approximately 18-hour median half-life.
-
Manageable Safety With One Dose-Limiting Toxicity
One DLT (AST/ALT elevation without bilirubin rise at 50 mg) among 56 patients; Grade 3/4 neutropenia in 4 patients (7%) with no febrile neutropenia, and two Grade 3 pneumonitis events (4%).
-
Enrollment Refocused on USC and Cyclin E PROC
Aprea plans to enroll at least 50 patients with uterine serous carcinoma or cyclin E-overexpressing platinum-resistant ovarian cancer, expanding to more than 10 sites, with dose escalation and backfill enrollment completion expected in Q2 2027.
Analysis · APRE · Life Sciences
Aprea's lead asset APR-1051 has delivered its first real clinical readout: two partial responses (one confirmed, on treatment beyond 10 months) in PPP2R1A-mutated uterine cancers, plus five stable-disease patients lasting over four months out of 56 treated. Equally important is the tolerability picture — a single dose-limiting toxicity and only 7% Grade 3/4 neutropenia with no febrile neutropenia — because prior WEE1 inhibitors were killed by narrow therapeutic windows. Enrollment is now being narrowed to uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer, with dose escalation and backfill enrollment targeted for completion in Q2 2027. For a company with a market value under $10 million, this is the evidence that determines whether the program is partnerable or fundable; the $37.8M cash position reported in the November 4 10-Q runs into Q1 2028, so the next hard constraint is the January 19, 2027 Nasdaq bid-price deadline, not cash.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, APRE was trading at $0.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7M. The 52-week trading range was $0.39 to $1.49. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.